Management of Metformin in Patients with Hepatic Impairment

Introduction to Metformin Use and Hepatic Impairment

• The American Diabetes Association recommends continuing an intensive insulin regimen that has achieved good glycemic control in patients with hepatic impairment, as metformin can be discontinued during this period if contraindications exist 1, 2.
• The American Diabetes Association guidelines support tapering insulin in patients meeting glucose targets, and metformin can be discontinued during this period if contraindications exist 1, 2.

Diagnostic Evaluation

• Consider hepatic ultrasound to evaluate for fatty liver disease or structural abnormalities in patients with hepatic impairment 4.

Risk Assessment and Management

• Hepatic impairment is a recognized risk factor for metformin-associated lactic acidosis (MALA), with a mortality rate ranging from 30-50% if not promptly treated 3.
• The American Diabetes Association recommends that patients initially treated with insulin who are meeting glucose targets can have insulin tapered over 2-6 weeks by decreasing doses 10-30% every few days 1, 2.

Alternative Therapies

• If additional non-insulin therapy is needed after liver function normalizes, consider GLP-1 receptor agonists as an alternative to metformin 1, 2.

Restarting Metformin

• Metformin may be reconsidered if liver enzymes and bilirubin return to normal baseline values, the underlying cause of hepatic dysfunction is identified and resolved, and there is no evidence of cirrhosis or chronic liver disease 5.
• If workup reveals non-alcoholic fatty liver disease (NAFLD) as the cause of transaminase elevation, metformin may actually be beneficial once acute injury resolves 4.